Scientific Reports (Feb 2021)

Importance of diagnosis-to-treatment interval in newly diagnosed patients with diffuse large B-cell lymphoma

  • Masahiro Yoshida,
  • Yosuke Nakaya,
  • Katsujun Shimizu,
  • Naoko Tatsumi,
  • Minako Tsutsumi,
  • Hoyuri Fuseya,
  • Mirei Horiuchi,
  • Takuro Yoshimura,
  • Yoshiki Hayashi,
  • Takafumi Nakao,
  • Takeshi Inoue,
  • Takahisa Yamane

DOI
https://doi.org/10.1038/s41598-021-82615-4
Journal volume & issue
Vol. 11, no. 1
pp. 1 – 7

Abstract

Read online

Abstract Treatment of patients with malignancy sometimes be delayed due to various reasons. Several studies revealed that an influence of diagnosis-to-treatment interval (DTI) on outcomes differs depending on the type of malignancy. In this study, we evaluated the influence of DTI on clinical outcomes in newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL). A total of 199 patients were identified with a median DTI of 22 days. At 2 years, patients with short DTI (0–22 days) showed significantly poorer OS (62.7% vs 86.4%) and PFS (55.1% vs 75.9%) compared to those with long DTI (over 22 days). Although short DTI was strongly correlated with several known adverse factors, it remained to be an independent prognostic factor by multivariate analysis. In conclusion, our study confirmed the importance of DTI in patients with DLBCL. Researchers should consider DTI as one of the important prognostic factors and plan clinical trials to be able to enroll patients with aggressive disease requiring urgent treatment.